Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development.
The pharma has already test-driven Science 37’s cloud-based, mobile telemedicine platform within three Phase II clinical trials and has concluded the approach can speed recruitment -- at least in some indications.
Novartis also hopes the platform will identify and enroll more diverse populations than typically participate in clinical trials.
“We want to completely flip the research paradigm and shift to a more patient-centered approach to reduce the burden on patients participating, democratize access for those that are remote and include those patients who are often understudied or represent underserved populations,” said Jacob LaPorte, global head of digital development at Novartis.
“We want to completely flip the research paradigm and shift to a more patient-centered approach.”
On March 7, the partners announced plans to add 10 Phase II and Phase III trials to their collaboration over the next three years in CNS, dermatology and cancer.
“The expectation is that we will be able to broaden